The regular emails and phone calls I get from patients asking questions about stem cell therapy are a powerful reminder of the fact that research in our field can be very personal. Sometimes individuals who receive experimental stem cell therapy (or other cell therapies) and seem to have a positive outcome can end up becoming […]
Overplaying N=1 in the stem cell therapy world Read More »
Some people consider the brain to be equivalent to a living computer and in that sense it’s too bad that computers don’t have the equal of neural stem cells to help them fix themselves. Is the internet one big neural network-like web? There was a quake in the stem cell internet as CIRM’s main website
Weekly reads: neural stem cells, CRISPR brain, Vertex, cytoplasm surprise Read More »
A planned change to the Google ads policy will allow some ads for unproven cell and gene therapies. This shift, allowing educational ads, was just announced. I have a few concerns about this change that will start in July. Google ads policy and stem cells This move seems to be a refinement of their “ad ban” policy
Google ads policy change to allow unproven cell & gene therapy educational material Read More »
If there’s one area of biologics where the FDA has been consistently busy lately it’s the perinatal cell therapy space. The agency has made it clear in the last year that allogeneic birth-related cell products are often drugs requiring premarket approval. This has mainly manifested at a practical enforcement level. We’ve seen actions taken in
End of FDA “grace period” impacted perinatal cell therapy biotechs Read More »
In trying to figure out how unproven stem cell clinics get so many customers, I’ve found that these firms can in part thank Google. I recently wrote a guest piece on STAT News about this problem and called on Google to fix it. However, just this week I stumbled on another case of Google search
Google gets it dangerously wrong on stem cell side effects Read More »
At the beginning of the year I wrote about a new kind of biotech called Altos Labs. It’s very different in some ways from other institutions. I find it an intriguing research entity. Where do things stand now with Altos Labs a few months later? More information, new ideas, and questions have popped up in the
Altos Labs: mission, leadership, jobs, & CIRM Read More »
How much promise is there today for stem cell therapy for heart disease? Where do things stand with the clinical research? Patients regularly ask me these kinds of questions. The goal of today’s post is to update you on where things stand. What’s in this post Stem Cell Therapy | Clinical Trials | Delivery of
Stem cell therapy for heart disease: what you need to know Read More »
When it comes to stem cells on Twitter and other social media, who do you follow now? Why them? Who are the top stem cell and regenerative medicine influencers to follow on Twitter and elsewhere in 2022? Stem cells on Twitter: great content amongst the noise Top stem cell and regenerative medicine influencers on Twitter.
50 influencers on stem cells on Twitter to follow in 2022 Read More »
It’s been quite a ride doing this blog on stem cells and other technologies for more than a dozen years. So far it seems like I’ll keep it going. A large part of the reason is because of people needing good information about our field. Those people include scientists and physicians but also many in
Weekly reads: Google, stem cells & MS, VSELs, ‘hairy’ organoids, MYC Read More »
It’s very challenging to be an academic scientist even under normal circumstances so when a government starts going after researchers for things like supposed irregularities in funding disclosures, it can cause serious problems if not carefully overseen. We’ll start this week’s recommended reads with the feds monitoring such disclosures and even making referrals to the
Weekly reads: Yale scientist suspended, WA AG sues clinic, new pubs Read More »